Clinical Trial Comparing Benzylpenicillin and Cloxacillin Treatments for Adults with Penicillin-Susceptible Staphylococcus Aureus Bloodstream Infection

What this Trial Is About

Researchers are evaluating whether benzylpenicillin is a better treatment than cloxacillin for adults with penicillin-susceptible Staphylococcus aureus bacteraemia PSSA. This randomized controlled trial aims to compare these two antibiotics to see which leads to better outcomes, such as survival without complications, in patients with this bloodstream infection. The study is planned as a nation-wide effort involving adult patients over 18 years old. Participants will be randomly assigned to receive either benzylpenicillin or cloxacillin after confirming penicillin susceptibility of the bacteria from blood cultures, which typically takes two to three days. The dosage and treatment length depend on the specific infection diagnosis, such as endocarditis or arthritis. Both drugs will be given at recommended doses adjusted for kidney function when needed. The study includes repeated blood cultures and heart ultrasounds as part of the evaluation process to monitor infection and treatment effects. During the study, participants will be closely monitored for side effects like liver or kidney problems, rash, diarrhea, and blood vessel inflammation, as well as treatment failure, relapse, and survival over 90 days after treatment ends. Researchers will assess survival without complications, relapse rates, antibiotic changes due to side effects or treatment failure, and bacterial DNA levels in blood samples during the first five days. The total participation time covers treatment and follow-up for 90 days to evaluate outcomes and safety.

Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia